Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 2/20 | 0.88 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.85 |
| ▸ | CNR1 | P21554 | 5/20 | 0.76 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.75 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.75 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.74 |
| ▸ | HPGD | P15428 | 2/20 | 0.74 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.74 |
| ▸ | MEN1 | O00255 | 1/20 | 0.74 |
| ▸ | MAPT | P10636 | 1/20 | 0.74 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.74 |
| ▸ | BLM | P54132 | 1/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.74 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6682385 | 1.00 | EPHX2 (0.88) | EPHX2SLC6A5CNR1KDM4ELPAR1 | |
| SCHEMBL5077840 | 1.00 | EPHX2 (0.88) | EPHX2SLC6A5CNR1KDM4ELPAR1 | |
| SCHEMBL3375110 | 1.00 | EPHX2 (0.88) | EPHX2SLC6A5CNR1KDM4ELPAR1 | |
| SCHEMBL25334864 | 1.00 | EPHX2 (0.88) | EPHX2SLC6A5CNR1KDM4ELPAR1 | |
| SCHEMBL195034 | 1.00 | EPHX2 (0.88) | EPHX2SLC6A5CNR1KDM4ELPAR1 | |
| SCHEMBL24233390 | 1.00 | EPHX2 (0.88) | EPHX2SLC6A5CNR1KDM4ELPAR1 | |
| SCHEMBL10481762 | 1.00 | EPHX2 (0.88) | EPHX2SLC6A5CNR1KDM4ELPAR1 | |
| SCHEMBL20987095 | 1.00 | EPHX2 (0.88) | EPHX2SLC6A5CNR1KDM4ELPAR1 | |
| SCHEMBL22716596 | 1.00 | EPHX2 (0.88) | EPHX2SLC6A5CNR1KDM4ELPAR1 | |
| SCHEMBL3375090 | 1.00 | EPHX2 (0.88) | EPHX2SLC6A5CNR1KDM4ELPAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7846972-B2 | Multimeric oleamide derivative having connexin-26 inhibiting potency and use thereof in cancer therapy, etc | The New Industrial Research Organization (JP) | 2010-12-07 | — | — | US | disclosed |
| US-20080089924-A1 | Multimeric Oleamide Derivative Having Connexin-26 Inhibiting Potency and Use Thereof in Cancer Therapy, etc. | THE RITSUMEIKAN TRUST (JP) | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080089924-A1 | Multimeric Oleamide Derivative Having Connexin-26 Inhibiting Potency and Use Thereof in Cancer Therapy, etc. | GJA1, GJB2, SLC26A3 | EPHX2 503/4885SLC6A5 518/4885CNR1 302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.